These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25297911)

  • 21. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
    von Websky K; Reichetzeder C; Hocher B
    Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Aletti R; Cheng-Lai A
    Cardiol Rev; 2012; 20(1):45-51. PubMed ID: 22143285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
    Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
    Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
    Graefe-Mody U; Retlich S; Friedrich C
    Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linagliptin: from bench to bedside.
    Doupis J
    Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Christensen M; Knop FK
    Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
    Rungby J
    Expert Opin Investig Drugs; 2009 Jun; 18(6):835-8. PubMed ID: 19426127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.